News | May 05, 2009

Breast Surgeons Meeting Discusses Laser Treatment for Benign Breast Tumors

May 5, 2009 - A panel at the recent meeting of the 10th Annual Meeting of the American Society of Breast Surgeons, held April 22-26 in San Diego, included discussion of the advantages of a new laser treatment for fibroadenomas, using the Novilase Breast Therapy to offer a minimally invasive alternative to lumpectomy.

Novilase Breast Therapy uses direct laser therapy to treat fibroadenomas. The system aims to treat these noncancerous tumors while minimizing risks and maintaining the breast’s natural shape and feel.

Among the panelists was Kambiz Dowlat, M.D., a professor of surgery at the Rush University Medical Center in Chicago. Dr. Dowlat pioneered laser treatment of small breast tumors. The procedure he developed is now performed with the Novilase Interstitial Laser Therapy device.

“With the X-ray guided laser technology we have today, lumpectomy is overkill,” said Dr. Dowlat. “Lumpectomy creates a significant scar and can deform the breast when you take the tumor out. Fibroadenomas can be precisely ablated with a laser, giving a superior result and less medical risk than lumpectomy. This is a great boon for patients because they can have their benign tumors treated without significant consequences for their health or appearance.”
Dr. Dowlat noted that breast health is moving toward treatments, such as Novilase, that are less invasive and have fewer side effects.
Tumors are now being detected at earlier stages when they are smaller. Because laser therapy is less intimidating for most women, the procedure provides them with a third treatment option besides surgery and a “watch and wait” approach, which may encourage them to take advantage of early detection.

Dr. Dowlat’s remarks emphasized several benefits of laser treatment over lumpectomy surgery, the traditional approach to treating fibroadenomas:
- Minimal scarring. Because no incision is made, laser treatment generally leaves only minimal scars.
- Natural shape and feel maintained. There is typically no “dimpling” with laser treatment because unlike a lumpectomy, the procedure does not remove tissue. In addition, the body’s natural healing process repairs the tumor site and restores the breast’s natural feel.
• Less risk of adverse reaction. Laser treatment can be performed using local anesthetic. A lumpectomy often requires IV sedation or a general anesthetic, which can be riskier.
• Less infection risk. The procedure involves the insertion of a laser probe and a thermal probe through two 1/8- inch skin nicks. The small size of the nicks keeps the infection risk extremely low. In contrast, a lumpectomy uses a 2 inch-to-3 inch incision, which creates a greater risk of infection.
• Faster recovery. A patient can resume normal activity within a few hours of the procedure. Recovery from a lumpectomy can take several days.
About 10 percent of all women will experience fibroadenomas during their lifetime. Although not cancerous, fibroadenomas can cause physical discomfort and also anxiety because of the association of lumps with breast cancer. Thus, after consultation with their physicians, many women with this condition request that their fibroadenomas be removed.

While Novilase uses direct laser therapy to treat fibroadenomas, laser ablation has been successfully used to treat benign prostate tumors. Novilase also uses the same image guidance for breast biopsy.

For more information: www.novianhealth.com

Related Content

MedStar Georgetown Proton Center Selects RayStation for Treatment Planning
News | Treatment Planning | August 17, 2017
August 17, 2017 — The proton center at MedStar Georgetown University Hospital will utilize RayStation for planning on
DOSIsoft Releases ISOgray Proton Therapy Treatment Planning System
Technology | Treatment Planning | August 15, 2017
DOSIsoft SA announced the official release, with CE marking, of ISOgray Treatment Planning System (TPS) release 4.3 for...
First Radixact Results Presented at AAPM 2017
News | Radiation Therapy | August 10, 2017
Accuray Inc. announced that the first studies validating the benefits of the Radixact System were presented at the 59th...
Clinical Data Supports Use of Xoft System for Endometrial Cancer
News | Brachytherapy Systems | August 03, 2017
Researchers presented clinical data supporting use of the Xoft Axxent Electronic Brachytherapy (eBx) System for the...
Aktina’s interchangeable cones are lightweight and extremely accurate
News | Radiation Therapy | August 02, 2017
Aktina Medical announced a collaboration with Philips Medical Systems and Elekta Instruments for SRS interlocking at...
The ASPIRE Cristalle FFDM system with DBT combines Fujifilm’s state-of-the-art hexagonal close pattern (HCP) detector design, advanced image processing and image acquisition workflow
News | Women's Health | August 01, 2017
Fujifilm Medical Systems U.S.A., Inc. announced that The Mammography Center of Monterey, an ACR-accredited breast...
News | Image Guided Radiation Therapy (IGRT) | July 31, 2017
Elekta’s magnetic resonance radiation therapy (MR/RT) system will be the subject of 21 abstracts at the 59th American...
Accuray Receives 510(k) Clearance for iDMS Data Management System
Technology | Oncology Information Management Systems (OIMS) | July 31, 2017
July 31, 2017 — Accuray Inc. announced it has received 510(k) clearance from the U.S.
more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Overlay Init